Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Walleye Capital LLC

Walleye Capital LLC boosted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 986.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 670,594 shares of the company's stock after purchasing an additional 608,874 shares during the quarter. Walleye Capital LLC owned about 0.98% of Amylyx Pharmaceuticals worth $2,173,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Alpha Wave Global LP bought a new stake in Amylyx Pharmaceuticals during the 3rd quarter valued at $2,169,000. FMR LLC boosted its position in Amylyx Pharmaceuticals by 292.0% during the 3rd quarter. FMR LLC now owns 221,001 shares of the company's stock valued at $716,000 after acquiring an additional 164,622 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Amylyx Pharmaceuticals by 41.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 880,745 shares of the company's stock valued at $2,854,000 after acquiring an additional 258,818 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Amylyx Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company's stock valued at $42,000 after acquiring an additional 5,104 shares in the last quarter. Finally, abrdn plc boosted its position in Amylyx Pharmaceuticals by 1,567.9% during the 3rd quarter. abrdn plc now owns 1,972,242 shares of the company's stock valued at $6,390,000 after acquiring an additional 1,853,995 shares in the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 11,442 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total value of $36,614.40. Following the sale, the insider now owns 143,801 shares of the company's stock, valued at approximately $460,163.20. The trade was a 7.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James M. Frates purchased 40,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, September 12th. The shares were bought at an average price of $2.53 per share, with a total value of $101,200.00. Following the completion of the transaction, the chief financial officer now owns 233,464 shares in the company, valued at approximately $590,663.92. This trade represents a 20.68 % increase in their position. The disclosure for this purchase can be found here. Insiders own 11.70% of the company's stock.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX traded down $0.09 during trading hours on Wednesday, hitting $5.26. The company had a trading volume of 655,465 shares, compared to its average volume of 1,975,355. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $19.95. The company has a market cap of $360.57 million, a PE ratio of -1.40 and a beta of -0.68. The business has a 50 day moving average of $4.76 and a 200-day moving average of $3.00.

Analyst Ratings Changes

AMLX has been the subject of a number of recent analyst reports. Baird R W raised Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. HC Wainwright lifted their price objective on Amylyx Pharmaceuticals from $8.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and lifted their price target for the company from $3.00 to $11.00 in a research note on Monday, November 18th. Leerink Partners set a $4.00 price objective on Amylyx Pharmaceuticals and gave the stock a "market perform" rating in a report on Friday, October 18th. Finally, Bank of America upgraded Amylyx Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $4.20 to $10.00 in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.43.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.